Anixa Biosciences, Inc. is a biotechnology company developing cancer therapies and vaccines. Its therapeutics program includes lira-cel, a chimeric endocrine receptor-T cell (CAR-T) therapy for ovarian cancer, developed by subsidiary Certainty Therapeutics. Its vaccine programs include a Phase 1-completed breast cancer vaccine targeting alpha-lactalbumin, an ovarian cancer vaccine targeting AMHR2-ED, and a discovery program for lung, colon, and prostate cancer vaccines. The company also conducts limited patent licensing activities.
Q2 FY2026 — expected 2026-09-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-12 | 2025-10-31 | 0001493152-26-001845 | EDGAR | 40K words |
| 2025-01-10 | 2024-10-31 | 0001493152-25-001787 | EDGAR | 40K words |
| 2024-01-16 | 2023-10-31 | 0001493152-24-002453 | EDGAR | 39K words |
| 2023-01-04 | 2022-10-31 | 0001493152-23-000346 | EDGAR | — |
| 2022-01-04 | 2021-10-31 | 0001493152-22-000302 | EDGAR | — |
| 2021-01-07 | 2020-10-31 | 0001493152-21-000456 | EDGAR | — |
| 2020-01-09 | 2019-10-31 | 0001513162-20-000009 | EDGAR | — |
| 2019-01-11 | 2018-10-31 | 0001513162-19-000016 | EDGAR | — |
| 2018-01-09 | 2017-10-31 | 0001513162-18-000006 | EDGAR | — |
| 2016-12-07 | 2016-10-31 | 0001513162-16-001096 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-09-09 | 2026-07-31 | 0001493152-26-041963 | EDGAR | 18K words |
| 2026-03-09 | 2026-01-31 | 0001493152-26-009370 | EDGAR | 15K words |
| 2025-09-10 | 2025-07-31 | 0001493152-25-013000 | EDGAR | 17K words |
| 2025-05-28 | 2025-04-30 | 0001641172-25-012701 | EDGAR | 17K words |
| 2025-03-11 | 2025-01-31 | 0001493152-25-009854 | EDGAR | 14K words |
| 2024-09-06 | 2024-07-31 | 0001493152-24-035335 | EDGAR | 17K words |
| 2024-06-04 | 2024-04-30 | 0001493152-24-022573 | EDGAR | 17K words |
| 2024-03-12 | 2024-01-31 | 0001493152-24-009683 | EDGAR | 14K words |
| 2023-09-06 | 2023-07-31 | 0001493152-23-031826 | EDGAR | 17K words |
| 2023-06-14 | 2023-04-30 | 0001493152-23-021271 | EDGAR | 17K words |
| 2023-03-17 | 2023-01-31 | 0001493152-23-007994 | EDGAR | 14K words |
| 2022-09-09 | 2022-07-31 | 0001493152-22-025490 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001493152-26-009699 | EDGAR | 1K words |
| 2026-02-09 | 0001493152-26-005702 | EDGAR | 1K words |
| 2025-12-12 | 0001493152-25-027321 | EDGAR | 1K words |
| 2025-03-21 | 0001493152-25-011151 | EDGAR | 0K words |
| 2024-11-08 | 0001493152-24-044224 | EDGAR | 2K words |
| 2024-05-08 | 0001493152-24-018170 | EDGAR | 1K words |
| 2024-03-22 | 0001493152-24-010995 | EDGAR | 0K words |
| 2023-12-07 | 0001493152-23-043932 | EDGAR | 2K words |
| 2023-04-17 | 0001493152-23-012483 | EDGAR | 1K words |
| 2023-03-10 | 0001493152-23-007172 | EDGAR | 0K words |
310 total filings indexed. 278 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000715446 |
| Ticker | ANIX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.anixa.com |
| Listed | 1983-10-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ANIX (~200 tokens, structured JSON with cryptographic provenance)